Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
BUSINESS
Sumitomo Offloads Entire Ulotaront Rights to Otsuka for Strategic Priorities
Sumitomo Pharma said on March 15 that it has revised a worldwide neuropsychiatric collaboration with Otsuka Pharmaceutical, handing over the exclusive rights to the partner for ulotaront, the lead compound among the four assets covered by the original deal. The…
To read the full story
Related Article
- Sumitomo/Otsuka’s Blockbuster Hopeful Ulotaront Misses Primary Goals in PIII Schizophrenia Studies
August 1, 2023
- Otsuka Collaboration “More Positive” than Solo Even If Profits Shared: Sumitomo Dainippon Chief
October 28, 2021
- CNS Alliance with Otsuka Expected to be Long-term: Sumitomo Dainippon Senior Executive
October 28, 2021
- Sumitomo Dainippon, Otsuka Ink Global Collaboration for 4 Neuropsychiatric Drugs
October 1, 2021
BUSINESS
- Alper Alptekin Becomes Japan President of Organon
April 2, 2025
- Sumitomo Pharma to Offload Asian Biz to Trader Marubeni
April 2, 2025
- Xocova’s US Rolling Submission Starts for COVID Post-Exposure Prophylaxis
April 2, 2025
- Shoichiro Ogawa to Lead Sun Pharma Japan
April 2, 2025
- FunPep Inks Research Pact with French Public Institute on Antibody-Inducing Peptides
April 2, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…